On September 16 ACT-AD hosted its Eighth Annual FDA/Alzheimer’s Disease Allies Meeting in North Bethesda, Md. This year’s meeting, “Assessing the Scientific Foundation for Alzheimer’s Disease Therapeutic Development,” focused on what is being done to improve understanding of Alzheimer’s disease pathology and prospects for Alzheimer’s disease clinical trials.
ACT-AD Executive Director Cynthia Bens said this year’s meeting took a “back-to-basics” approach in the discussion of Alzheimer’s disease, with presentations on what clinical trials have revealed, the changing conceptualization of the disease, and what experts are learning about AD genetics.
“Today’s meeting offered an opportunity for attendees to frankly discuss what can be done to improve our prospects for treatment of Alzheimer’s disease,” said Bens. “We are very appreciative for the valuable insights shared by everyone.”
The meeting brought together a distinguished group of presenters, including Rachelle Doody, M.D., Ph.D., Baylor College of Medicine, George Perry, Ph.D., The University of Texas San Antonio, and Bryan Traynor, M.D., Ph.D., MMSc, MRCPI, National Institute on Aging. The meeting also included a panel of experts who participated in a vigorous discussion on scientific and regulatory considerations for advancing pre-clinical Alzheimer’s disease therapeutic development.
Perry, a member of ACT-AD’s Scientific Advisory Board, noted, “Today was remarkable. I came away encouraged from this meeting because of the honesty of the discussions regarding the status of clinical trials and their underlying biological and clinical endpoint assumptions. It is clear that we need to continue to make good progress to help families who are affected by Alzheimer’s disease and to build on the success of current approved therapeutics.”
The meeting agenda can be found here. ACT-AD will be posting additional details from the meeting at a future date.